A multicenter, prospective, randomized clinical trial to investigate the radical extent of lymphadenectomy of laparoscopic right colectomy for colon cancer (RELARC trial), directed by Prof. Xiao Yi of the general surgery department of PUMCH, had fulfilled its phased goals. The meeting of the researchers was held at PUMCH on March the 6th, 2021, where Prof. Zhao Yupei, the honorary president of PUMCH, and more than 50 experts were present. They reviewed the achievements of the program and engaged deeply in the discussion of the future study. According to the current results, despite an increased risk of vessels damage, the complete mesocolon excision (CME) does not lead to an increased incidence of intra-/post-operative complications. These findings have been published on the renowned journal “Lancet Oncology”, which signifies the high quality of this multicenter trial by the Chinese colorectal surgeons and its approval worldwide. The research team will continue to focus on its future works, including follow-up of the patients, evaluation of the long-term outcomes such as post-operation recurrence, overall survival and disease-free survival.  

Experts and Research fellows of “RELARC trial” presented at the meeting.

Correspondent: Lu Junyang, Xu Lai

Reporter: Gan Dingzhu

Photo: Sun Liang

Translator: Hou Rui

Editor: Yang Hongbo